SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra ...

ZURICH, July 19 (Reuters) - Roche's Japanese subsidiary Chugai said on Tuesday subcutaneous injection of its Actemra drug has shown efficacy in rheumatoid arthritis compared to intravenous infusion.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has issued an ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the global Phase III randomized, double-blind, multicenter ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Actemra? Actemra contains the active ingredient ...

The FDA said June 24 it has authorized Genentech’s Actemra for treatment of hospitalized COVID-19 patients. Actemra, an intravenous infusion drug with the generic name tocilizumab, is FDA-approved to ...

– Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease that can significantly impact lung function and can be life-threatening – – In a global ...

The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD. The Food and Drug Administration (FDA) has approved ...

Respiratory.ventilation Patients treated with tocilizumab were 44% less likely to progress to mechanical ventilation or death compared with placebo. Genentech announced that a phase 3 study assessing ...

Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment “Biosimilars continue to be a key growth driver for Organon, and this acquisition complements ...

Tocilizumab-anoh is approved for multiple conditions, including rheumatoid arthritis and COVID-19, in intravenous and subcutaneous formulations. Phase 3 study confirmed biosimilarity between ...

GenentechMedia:Joe St. Martin, 650-467-6800orInvestor:Thomas Kudsk Larsen, 650-467-2016Karl Mahler, 011 41 61 687 85 03 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today ...